Matrix metalloproteinases

spinqualitylabelsall models PDB ID 2clt Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image
Human MMP1 complex with Ca+2 and Zn+2 ions, 2clt
Ligands:	,
Activity:	Interstitial collagenase, with EC number 3.4.24.7
Related:	1ayk, 1cge, 1cgf, 1cgl, 1hfc, 1su3, 2ayk, 2tcl, 3ayk, 4ayk, 966c
Structural annotation: Resources: CATH : 2Clta02, 2Clta01, 2Cltb01, 2Cltb02 InterPro : Ipr002477, Ipr001818, Ipr006026, Ipr000585, Ipr006025 Pfam : PF00045, PF00413 UniProt : P03956
Functional annotation: Cellular component: proteinaceous extracellular matrix extracellular space Biological process: metabolic process collagen catabolic process proteolysis Molecular function: zinc ion binding hydrolase activity peptidase activity metal ion binding catalytic activity calcium ion binding collagenase activity metallopeptidase activity interstitial collagenase activity metalloendopeptidase activity
Evolutionary conservation: Toggle Conservation Colors: Rows = identical sequences: Further Information: Caveats, Explanation, Complete Results at ConSurfDB
Resources:	FirstGlance, OCA, RCSB, PDBsum
Coordinates:	save as pdb, mmCIF, xml

Endopeptidases involved in the degradation of the extracellular matrixEndopeptidases involved in the degradation of the extracellular matrix

The matrix metalloproteinases (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis. As a consequence, the MMP family has emerged as an attractive pharmaceutical target. Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention.

3D structures of MMP3D structures of MMP

Matrix metalloproteinase